Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research note published on Sunday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Several other research firms also recently commented on MRNS. Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average price target of $4.79.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.55 on Friday. The firm has a market cap of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. The firm’s 50 day simple moving average is $0.53 and its 200-day simple moving average is $0.82. Marinus Pharmaceuticals has a one year low of $0.22 and a one year high of $9.69.

Institutional Trading of Marinus Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in the stock. Suvretta Capital Management LLC grew its position in shares of Marinus Pharmaceuticals by 32.8% during the third quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock worth $8,930,000 after acquiring an additional 1,253,901 shares during the last quarter. Franklin Resources Inc. boosted its position in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after purchasing an additional 1,219,871 shares in the last quarter. Beryl Capital Management LLC acquired a new position in shares of Marinus Pharmaceuticals in the fourth quarter worth about $2,262,000. abrdn plc boosted its holdings in shares of Marinus Pharmaceuticals by 146.1% in the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock worth $4,679,000 after buying an additional 1,578,329 shares during the period. Finally, Woodline Partners LP boosted its holdings in shares of Marinus Pharmaceuticals by 84.7% in the fourth quarter. Woodline Partners LP now owns 2,335,681 shares of the biopharmaceutical company’s stock worth $1,250,000 after buying an additional 1,071,410 shares during the period. 98.80% of the stock is owned by institutional investors and hedge funds.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.